FDA Approves Ennumo (pegfilgrastim-pccg), a Biosimilar to Neulasta

BLA FilingapprovedEnnumoNeulastaPositive

AI Analysis

Summary

FDA approved Ennumo (pegfilgrastim-pccg), a biosimilar developed by Accord BioPharma to Neulasta. This marks a regulatory approval for a biosimilar oncology therapeutic candidate.

Outcome Details

FDA approved Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta

Importance:8/10

Sentiment:

0.80

biosimilarFDA approvaloncologypegfilgrastimNeulasta

Related Companies

$DFPH

Read the original article

Published by Drugs.com New Drug Approvals on July 9, 2026 8:05 PM

Read Original